Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from idiopathic pulmonary fibrosis

被引：0
|
作者：
Hostettler, Katrin [1 ]
Papakonstantinou, Eleni [2 ]
Klagas, Ioannis [2 ]
Karakiulakis, George [2 ]
Tamm, Michael [3 ]
Lardinois, Didier [4 ]
Roth, Michael [1 ]
机构：
[1] Univ Hosp, Dept Biomed, CH-4031 Basel, BS, Switzerland
[2] Aristotle Univ Thessaloniki, Sch Med, Lab Pharmacol, Thessaloniki 54124, Greece
[3] Univ Hosp, Clin Resp Med, CH-4031 Basel, BS, Switzerland
[4] Univ Hosp, Div Thorac Surg, CH-4031 Basel, BS, Switzerland
来源：
EUROPEAN RESPIRATORY JOURNAL | 2012年 / 40卷
关键词：
Idiopathic pulmonary fibrosis;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
2602
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Anti-Fibrotic Effects Of Nintedanib (bibf 1120) In Primary Human Lung Fibroblasts Derived From Patients With Idiopathic Pulmonary Fibrosis And From Non-Fibrotic Controls
    Hostettler, K. E.
    Papakonstantinou, E.
    Klagas, J.
    Karakiulakis, G.
    Zhong, J.
    Tamm, M.
    Lardinois, D.
    Roth, M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [2] Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin E.
    Zhong, Jun
    Papakonstantinou, Eleni
    Karakiulakis, George
    Tamm, Michael
    Seidel, Petra
    Sun, Qingzhu
    Mandal, Jyotshna
    Lardinois, Didier
    Lambers, Christopher
    Roth, Michael
    [J]. RESPIRATORY RESEARCH, 2014, 15
  • [3] Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Katrin E Hostettler
    Jun Zhong
    Eleni Papakonstantinou
    George Karakiulakis
    Michael Tamm
    Petra Seidel
    Qingzhu Sun
    Jyotshna Mandal
    Didier Lardinois
    Christopher Lambers
    Michael Roth
    [J]. Respiratory Research, 15
  • [4] Nintedanib (BIBF 1120) prevents TGF-β-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin
    Papakonstantinou, Eleni
    Zhong, Jun
    Karakiulakis, George
    Lardinois, Didier
    Tamm, Michael
    Roth, Michael
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [5] Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin
    Papakonstantinou, Eleni
    Klagas, Ioannis
    Bonovolias, Ioannis
    Sun, Qingzhu
    Tamm, Michael
    Lambers, Christopher
    Roth, Michael
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [6] Anti-Fibrotic Effects Of Nintedanib On Lung Fibroblasts
    Rangarajan, S.
    Kurundkar, A.
    Kurundkar, D.
    Bernard, K.
    Sanders, Y.
    Ding, Q.
    Zhang, J.
    Zmijewski, J.
    Thannickal, V. J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [7] Anti-Fibrotic Effects of Azithromycin in Human Lung Fibroblasts from Idiopathic Pulmonary Fibrosis Patients Compared to Control Fibroblasts
    Funke, M.
    Krempaska, K.
    Schliep, R.
    Knudsen, L.
    Geiser, T. K.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [8] A HUMAN MODEL OF LUNG FIBROSIS FOR THE ASSESSMENT OF ANTI-FIBROTIC STRATEGIES IN IDIOPATHIC PULMONARY FIBROSIS
    Roach, K. M.
    Tongue, P.
    Castells, E.
    Elliot, G.
    Marshall, H.
    Richardson, M.
    Mason, S.
    Chachi, L.
    Bradding, P.
    [J]. THORAX, 2019, 74 : A56 - A57
  • [9] Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis
    Sugino, Keishi
    Ono, Hirotaka
    Saito, Mikako
    Ando, Masahiro
    Tsuboi, Eiyasu
    [J]. PLOS ONE, 2024, 19 (06):
  • [10] A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
    Roach, Katy M.
    Sutcliffe, Amanda
    Matthews, Laura
    Elliott, Gill
    Newby, Chris
    Amrani, Yassine
    Bradding, Peter
    [J]. SCIENTIFIC REPORTS, 2018, 8
12345